Dr. Balar on Current and Future Standards of Care in Kidney Cancer Treatment

Arjun V. Balar, MD
Published: Monday, Jan 29, 2018



Arjun V. Balar, MD, assistant professor, Department of Medicine, director, Genitourinary Medical Oncology Program, NYU Langone’s Perlmutter Cancer Center, discusses the potential of existing targeted therapy coupled with immunotherapy to improve overall survival (OS) in patients with kidney cancer.

In kidney cancer, VEGF-targeted agents are already a standard of care in treating the disease. Because these tumors are immune-responsive, phase I data of the combinations of axitinib (Inlyta) plus pembrolizumab (Keytruda), axitinib plus avelumab (Bavencio), and most recently pembrolizumab plus lenvatinib (Lenvima) are demonstrating very promising response rates upwards of 70%. This demonstrates that there may be synergy between these agents to generate a more effective antitumor immune response.

Ultimately, these agents will lead to new standards of care in the first-line setting. Ongoing randomized trials hope to demonstrate that this combinatorial approach will lead to durable responses and better OS. 
 


Arjun V. Balar, MD, assistant professor, Department of Medicine, director, Genitourinary Medical Oncology Program, NYU Langone’s Perlmutter Cancer Center, discusses the potential of existing targeted therapy coupled with immunotherapy to improve overall survival (OS) in patients with kidney cancer.

In kidney cancer, VEGF-targeted agents are already a standard of care in treating the disease. Because these tumors are immune-responsive, phase I data of the combinations of axitinib (Inlyta) plus pembrolizumab (Keytruda), axitinib plus avelumab (Bavencio), and most recently pembrolizumab plus lenvatinib (Lenvima) are demonstrating very promising response rates upwards of 70%. This demonstrates that there may be synergy between these agents to generate a more effective antitumor immune response.

Ultimately, these agents will lead to new standards of care in the first-line setting. Ongoing randomized trials hope to demonstrate that this combinatorial approach will lead to durable responses and better OS. 
 



View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: Personalized Sequencing in Castration-Resistant Prostate Cancer: Bridging the Latest Evidence to the Bedside in Clinical ManagementAug 25, 20181.5
Community Practice Connections™: Bridging the Gaps Around Oncology Biosimilars: Assessing the Potential Impact of Emerging Agents to PracticeSep 29, 20181.5
Publication Bottom Border
Border Publication
x